Department of Microbiology and Immunology, Carver College of Medicine, The University of Iowagrid.214572.7, Iowa City, Iowa, USA.
J Virol. 2022 Jul 13;96(13):e0040622. doi: 10.1128/jvi.00406-22. Epub 2022 Jun 6.
The antibody response against the HIV-1 envelope glycoproteins (Envs) guides evolution of this protein within each host. Whether antibodies with similar target specificities are elicited in different individuals and affect the population-level evolution of Env is poorly understood. To address this question, we analyzed properties of emerging variants in the gp41 fusion peptide-proximal region (FPPR) that exhibit distinct evolutionary patterns in HIV-1 clade B. For positions 534, 536, and 539 in the FPPR, alanine was the major emerging variant. However, 534A and 536A show a constant frequency in the population between 1979 and 2016, whereas 539A is gradually increasing. To understand the basis for these differences, we introduced alanine substitutions in the FPPR of primary HIV-1 strains and examined their functional and antigenic properties. Evolutionary patterns could not be explained by fusion competence or structural stability of the emerging variants. Instead, 534A and 536A exhibited modest but significant increases in sensitivity to antibodies against the membrane-proximal external region (MPER) and gp120-gp41 interface. These Envs were also more sensitive to poorly neutralizing sera from HIV-1-infected individuals than the clade ancestral form or 539A variant. Competition binding assays confirmed for all sera tested the presence of antibodies against the base of the Env trimer that compete with monoclonal antibodies targeting the MPER and gp120-gp41 interface. Our findings suggest that weakly neutralizing antibodies against the trimer base are commonly elicited; they do not exert catastrophic population size reduction effects on emerging variants but, instead, determine their set point frequencies in the population and historical patterns of change. Infection by HIV-1 elicits formation of antibodies that target the viral Env proteins and can inactivate the virus. The specific targets of these antibodies vary among infected individuals. It is unclear whether some target specificities are shared among the antibody responses of different individuals. We observed that antibodies against the base of the Env protein are commonly elicited during infection. The selective pressure applied by such antibodies is weak. As a result, they do not completely eliminate the sensitive forms of the virus from the population, but maintain their frequency at a low level that has not increased since the beginning of the AIDS pandemic. Interestingly, the changes in Env do not occur at the sites targeted by the antibodies, but at a distinct region of Env, the fusion peptide-proximal region, which regulates their exposure.
针对 HIV-1 包膜糖蛋白(Env)的抗体反应指导了该蛋白在每个宿主内的进化。在不同个体中是否会产生具有相似靶特异性的抗体,以及这些抗体是否会影响 Env 的群体水平进化,目前还知之甚少。为了解决这个问题,我们分析了 HIV-1 分支 B 中具有不同进化模式的 gp41 融合肽近端区(FPPR)中新兴变体的特性。对于 FPPR 中的 534、536 和 539 位,丙氨酸是主要的新兴变体。然而,534A 和 536A 在 1979 年至 2016 年间在人群中的频率保持不变,而 539A 则逐渐增加。为了了解这些差异的基础,我们在原发性 HIV-1 株的 FPPR 中引入了丙氨酸取代,并研究了它们的功能和抗原特性。进化模式不能用融合能力或新兴变体的结构稳定性来解释。相反,534A 和 536A 对针对膜近端外区(MPER)和 gp120-gp41 界面的抗体的敏感性有适度但显著的增加。这些 Env 对来自 HIV-1 感染个体的低效中和血清也比分支祖形式或 539A 变体更敏感。竞争结合测定法证实,在所测试的所有血清中,存在针对 Env 三聚体基部的抗体,这些抗体与针对 MPER 和 gp120-gp41 界面的单克隆抗体竞争。我们的研究结果表明,针对三聚体基部的弱中和抗体通常被诱导产生;它们对新兴变体不会产生灾难性的种群数量减少效应,而是决定它们在种群中的设定点频率和历史变化模式。 HIV-1 感染会引发针对病毒 Env 蛋白的抗体形成,从而使病毒失活。这些抗体的特定靶标在受感染个体中有所不同。目前尚不清楚不同个体的抗体反应是否具有某些共同的靶特异性。我们观察到,在感染过程中通常会诱导针对 Env 蛋白基部的抗体。这种抗体的选择压力较弱。因此,它们并没有将病毒的敏感形式从人群中完全消除,而是将其频率维持在自艾滋病大流行开始以来一直没有增加的低水平。有趣的是,Env 的变化不是发生在抗体的靶标部位,而是发生在 Env 的一个独特区域,即融合肽近端区,该区域调节它们的暴露。